Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type
BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies
Low grade serous ovarian carcinoma: identifying variations in practice patterns
Management of Rare Ovarian Cancer Histologies
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Previous
Previous
2020
Next
Next